

# Robert J De Knegt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7628837/publications.pdf>

Version: 2024-02-01

186  
papers

7,532  
citations

66343

42  
h-index

58581

82  
g-index

190  
all docs

190  
docs citations

190  
times ranked

9912  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study. <i>Hepatology</i> , 2023, 77, 585-593.	7.3	17
2	Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 1967-1973.	4.0	11
3	Activated CD4+ T Cells and Highly Differentiated Alloreactive CD4+ T Cells Distinguish Operationally Tolerant Liver Transplantation Recipients. <i>Liver Transplantation</i> , 2022, 28, 98-112.	2.4	8
4	Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. <i>Hepatology</i> , 2022, 75, 419-429.	7.3	64
5	Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease – implications for the clinical utility of the EASL NIT guideline. <i>Journal of Hepatology</i> , 2022, 76, 245-246.	3.7	12
6	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. <i>Hepatology</i> , 2022, 75, 219-228.	7.3	107
7	Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 183-195.	8.9	6
8	Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. <i>Liver International</i> , 2022, 42, 277-287.	3.9	60
9	Reply to: "Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population". <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	4.4	0
10	The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures. <i>Viruses</i> , 2022, 14, 16.	3.3	3
11	Disease burden and management of Crigler-Najjar syndrome: Report of a world registry. <i>Liver International</i> , 2022, 42, 1593-1604.	3.9	8
12	Discrepancy between NAFLD and MAFLD – is it only due to misclassification of MAFLD?. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	4.4	0
13	The transition from NAFLD to MAFLD: One size still does not fit all – Time for a tailored approach?. <i>Hepatology</i> , 2022, 76, 1243-1245.	7.3	8
14	Hepatitis C Elimination in the Netherlands (CELINE): How nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination. <i>European Journal of Internal Medicine</i> , 2022, 101, 93-97.	2.2	6
15	Reply to: "Epragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD". <i>Hepatology Communications</i> , 2022, 6, 2605-2606.	4.3	0
16	Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2022, 227, 113-122.	4.0	8
17	Association of Nonalcoholic Fatty Liver Disease and Fibrosis With Incident Dementia and Cognition. <i>Neurology</i> , 2022, 99, .	1.1	23
18	Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. <i>Obesity Reviews</i> , 2022, 23, .	6.5	7

#	ARTICLE	IF	CITATIONS
19	Tamoxifen use and potential effects on liver parenchyma: A long-term prospective transient elastographic evaluation. <i>Hepatology Communications</i> , 2022, 6, 2565-2568.	4.3	1
20	Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1933-1940.e1.	4.4	14
21	Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults. <i>Hepatology</i> , 2021, 73, 968-982.	7.3	43
22	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , 2021, 74, 1053-1063.	3.7	68
23	Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption. <i>Nature Communications</i> , 2021, 12, 2830.	12.8	35
24	The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030. <i>Journal of Clinical Medicine</i> , 2021, 10, 4562.	2.4	9
25	Sex-specific normal values and determinants of infrarenal abdominal aortic diameter among non-aneurysmal elderly population. <i>Scientific Reports</i> , 2021, 11, 17762.	3.3	6
26	Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100350.	4.9	52
27	Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 314-320.	3.7	19
28	Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 432-442.	3.7	9
29	Current Tolerance-Associated Peripheral Blood Gene Expression Profiles After Liver Transplantation Are Influenced by Immunosuppressive Drugs and Prior Cytomegalovirus Infection. <i>Frontiers in Immunology</i> , 2021, 12, 738837.	4.8	1
30	Editorial: HBV cure—the quest for biomarkers to predict off-treatment sustained response. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 555-556.	3.7	0
31	Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls. <i>Journal of Infectious Diseases</i> , 2020, 224, 443-452.	4.0	6
32	Objectives, design and main findings until 2020 from the Rotterdam Study. <i>European Journal of Epidemiology</i> , 2020, 35, 483-517.	5.7	314
33	Editorial: rapid disease progression in hepatitis delta—can we turn the tide?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 172-173.	3.7	2
34	NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse. <i>Hepatology</i> , 2020, 71, 774-776.	7.3	6
35	Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population. <i>European Journal of Epidemiology</i> , 2020, 35, 1069-1085.	5.7	35
36	Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1399-1406.	3.7	25

#	ARTICLE	IF	CITATIONS
37	High Risk of Infection During Triple Therapy with First- Generation Protease Inhibitors: A Nationwide Cohort Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 197-204.	0.9	3
38	Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. <i>Gut</i> , 2019, 68, 1088-1098.	12.1	97
39	FRI-163-Reduced liver-related complications after 13 years of follow-up of interferon-alpha treatment for HBeAg-positive chronic hepatitis B: The ELITE-B study. <i>Journal of Hepatology</i> , 2019, 70, e460.	3.7	0
40	THU-169-Genotype 4 RAS patterns in a European hepatitis C cohort. <i>Journal of Hepatology</i> , 2019, 70, e236.	3.7	0
41	FRI-206-Relationship between hepatitis B core related antigen levels and sustained HBeAg seroconversion in patients treated with nucleos (t)ide analogues. <i>Journal of Hepatology</i> , 2019, 70, e484.	3.7	0
42	Diet-Dependent Acid Loadâ€”The Missing Link Between an Animal Proteinâ€”Rich Diet and Nonalcoholic Fatty Liver Disease?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6325-6337.	3.6	14
43	Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Criglerâ€”Najjar Syndrome. <i>Human Gene Therapy</i> , 2019, 30, 1297-1305.	2.7	39
44	Hepatitis C Core-Antigen Testing from Dried Blood Spots. <i>Viruses</i> , 2019, 11, 830.	3.3	19
45	Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. <i>PLoS ONE</i> , 2019, 14, e0210179.	2.5	32
46	Hepatitis B coreâ€”related antigen monitoring during peginterferon alfa treatment for HBeAgâ€”negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1156-1163.	2.0	17
47	Diagnostic and analytical performance of the hepatitis B core related antigen immunoassay in hepatitis B patients. <i>Journal of Clinical Virology</i> , 2019, 114, 1-5.	3.1	13
48	Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 538-544.	8.1	49
49	Gene expression profiling of human tissueâ€”resident immune cells: Comparing blood and liver. <i>Journal of Leukocyte Biology</i> , 2019, 105, 603-608.	3.3	11
50	Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring. <i>Journal of Hepatology</i> , 2019, 70, 552-554.	3.7	14
51	Immunosuppressive drug withdrawal late after liver transplantation improves the lipid profile and reduces infections. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1444-1451.	1.6	5
52	Younger age and language barriers are associated with nonadherence to clinical followâ€”up in hepatitis B treatment. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1216-1219.	2.0	2
53	Adherence to quality criteria improves concordance between transient elastography and ElastPQ for liver stiffness assessmentâ€”A multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2018, 50, 1056-1061.	0.9	29
54	Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals. <i>Gastroenterology</i> , 2018, 154, 515-517.e3.	1.3	96

#	ARTICLE	IF	CITATIONS
55	Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study. <i>Journal of Hepatology</i> , 2018, 68, S555.	3.7	0
56	Mucosal-associated invariant T cell frequency and function in blood and liver of HCV mono- and HCV/HIV co-infected patients with advanced fibrosis. <i>Liver International</i> , 2018, 38, 458-468.	3.9	39
57	HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 856-864.	8.1	43
58	Can point shear wave elastography differentiate focal nodular hyperplasia from hepatocellular adenoma. <i>Journal of Clinical Ultrasound</i> , 2018, 46, 380-385.	0.8	12
59	Serum immune signatures predict HCC development in DAA-treated HCV patients. <i>Journal of Hepatology</i> , 2018, 68, S528.	3.7	0
60	TLR7 polymorphism, sex and chronic HBV infection influence plasmacytoid DC maturation by TLR7 ligands. <i>Antiviral Research</i> , 2018, 157, 27-37.	4.1	16
61	Therapeutic Drug Monitoring of DAAs overcomes contraindications against anti-epileptics in HCV treatment (HepNed003). <i>Journal of Hepatology</i> , 2018, 68, S288-S289.	3.7	0
62	NK cell phenotypic and functional shifts coincide with specific clinical phases in the natural history of chronic HBV infection. <i>Antiviral Research</i> , 2017, 140, 18-24.	4.1	21
63	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). <i>Ultraschall in Der Medizin</i> , 2017, 38, e16-e47.	1.5	659
64	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version). <i>Ultraschall in Der Medizin</i> , 2017, 38, 377-394.	1.5	93
65	MAIT cell frequency and function in blood and liver of hepatitis C virus mono- and hepatitis C virus/human immunodeficiency virus co-infected patients with mild versus advanced fibrosis. <i>Journal of Hepatology</i> , 2017, 66, S326-S327.	3.7	0
66	Interferon-free antiviral therapy for chronic hepatitis C among patients in the liver transplant setting. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 219-225.	2.4	6
67	The Path to Cancer and Back. <i>Transplantation</i> , 2017, 101, 910-915.	1.0	23
68	Characterization of the intrahepatic immune response of virally-suppressed chronic hepatitis B patients to treatment with the oral TLR7 agonist GS-9620. <i>Journal of Hepatology</i> , 2017, 66, S478-S479.	3.7	1
69	Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation. <i>Clinical Infectious Diseases</i> , 2017, 65, 680-683.	5.8	30
70	Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON). <i>Journal of Infectious Diseases</i> , 2017, 215, 1085-1093.	4.0	46
71	Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1023-1031.	2.0	24
72	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	8.1	208

#	ARTICLE	IF	CITATIONS
73	Mucosal-Associated Invariant T Cells Are More Activated in Chronic Hepatitis B, but Not Depleted in Blood: Reversal by Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 216, 969-976.	4.0	37
74	Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 864-872.	3.7	2
75	Why should dermatologists think of liver fibrosis?. <i>British Journal of Dermatology</i> , 2017, 177, 610-611.	1.5	0
76	Clinical evaluation of hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, S480.	3.7	0
77	A Model-Based Prediction of the Probability of Hepatocellular Adenoma and Focal Nodular Hyperplasia Based on Characteristics on Contrast-Enhanced Ultrasound. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 2144-2150.	1.5	10
78	Multiple biopsy passes and the risk of complications of percutaneous liver biopsy. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 36-41.	1.6	65
79	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2017, 66, 485-493.	3.7	225
80	Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. <i>Frontiers in Immunology</i> , 2017, 8, 621.	4.8	48
81	Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B. <i>Clinical and Experimental Gastroenterology</i> , 2017, Volume 10, 203-209.	2.3	9
82	Epidemiological Trends among the Population with Chronic HCV Infection in the Netherlands. <i>Antiviral Therapy</i> , 2016, 21, 207-215.	1.0	0
83	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1821-1830.e6.	4.4	61
84	HCV treatment in liver transplantation: timing is the challenge. <i>Transplant International</i> , 2016, 29, 1067-1069.	1.6	1
85	Flares during long-term entecavir therapy in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1882-1887.	2.8	10
86	Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1851-1859.	2.8	4
87	How to diagnose and manage hepatic encephalopathy. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 146-152.	1.6	31
88	Polymorphisms of HLA-DPB1 are Associated with Long-Term Clinical Outcome in a Diverse Cohort of Chronic Hepatitis B Patients. <i>Journal of Hepatology</i> , 2016, 64, S380.	3.7	0
89	NK Cells from Chronic HBV Patients in Different Clinical Phase Exhibit Altered Gene Expression Profiles by RNA-SEQ. <i>Journal of Hepatology</i> , 2016, 64, S384-S385.	3.7	0
90	Sustained Virological Response Results in Regression of Liver Stiffness in Patients with Chronic Hepatitis C Virus Infection. <i>Journal of Hepatology</i> , 2016, 64, S731.	3.7	0

#	ARTICLE	IF	CITATIONS
91	Safety of Direct-Acting Antivirals-Based Therapy for the Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis: Results from an International Multicenter Cohort Study. <i>Journal of Hepatology</i> , 2016, 64, S812-S813.	3.7	3
92	Similar Frequencies, Phenotype and Activation Status of Intrahepatic NK Cells in Chronic HBV Patients after Long-Term Treatment with Tenofovir Disoproxil Fumarate (TDF). <i>Journal of Hepatology</i> , 2016, 64, S389-S390.	3.7	0
93	Do Mucosal-Associated Invariant T (Mait) Cells Impact Fibrosis in HCV and HIV/HCV Co-Infected Patients?. <i>Journal of Hepatology</i> , 2016, 64, S509.	3.7	0
94	Drug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1471-1494.	3.5	27
95	Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF). <i>Antiviral Research</i> , 2016, 132, 70-75.	4.1	18
96	Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1168-1176.	2.8	44
97	Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment. <i>Journal of Infectious Diseases</i> , 2016, 213, 216-223.	4.0	145
98	Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Clinical Microbiology and Infection</i> , 2016, 22, 571.e5-571.e9.	6.0	22
99	Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction. <i>Journal of Hepatology</i> , 2016, 64, 1274-1282.	3.7	64
100	Frequencies of Circulating MAIT Cells Are Diminished in Chronic HCV, HIV and HCV/HIV Co-Infection and Do Not Recover during Therapy. <i>PLoS ONE</i> , 2016, 11, e0159243.	2.5	63
101	Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0161821.	2.5	8
102	The ARRIBA concept: adequate resorption of ribavirin. <i>Antiviral Therapy</i> , 2015, 20, 515-520.	1.0	2
103	Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. <i>BMC Infectious Diseases</i> , 2015, 15, 371.	2.9	31
104	Prominent HLA-G Expression in Liver Disease But Not After Liver Transplantation. <i>Transplantation</i> , 2015, 99, 2514-2522.	1.0	6
105	ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection. <i>PLoS ONE</i> , 2015, 10, e0139317.	2.5	15
106	Cost Per Patient With Sustained Viral Response for Ombitasvir/Paritaprevir/Ritonavir And Dasabuvir With or Without Ribavirin In Genotype 1 Patients With Chronic Hcv In The Netherlands. <i>Value in Health</i> , 2015, 18, A586.	0.3	0
107	Cost-Effectiveness of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Patients With Chronic Hcv in the Netherlands. <i>Value in Health</i> , 2015, 18, A588.	0.3	1
108	Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 2021-9.	2.3	10

#	ARTICLE	IF	CITATIONS
109	High-dose (peg)interferon therapy in treatment-naïve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2015, 47, 87-88.	0.9	1
110	Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries â€“ volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 6-25.	2.0	92
111	Strategies to manage hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infection disease burden â€“ volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 46-73.	2.0	47
112	CD4+CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses. <i>Journal of Hepatology</i> , 2015, 62, 303-310.	3.7	51
113	The present and future disease burden of hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infections with today's treatment paradigm â€“ volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 26-45.	2.0	117
114	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. <i>Gut</i> , 2015, 64, 1289-1295.	12.1	178
115	The Intrahepatic T Cell Compartment Does Not Normalize Years After Therapy-Induced Hepatitis C Virus Eradication. <i>Journal of Infectious Diseases</i> , 2015, 212, 386-390.	4.0	26
116	Risk of infections during interferonâ€“based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1057-1064.	2.8	4
117	P0613 : Hepatitis B core related antigen may be a marker for immune control in HBeAg negative chronic hepatitis B infection. <i>Journal of Hepatology</i> , 2015, 62, S547.	3.7	0
118	P0661 : Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count: Results from a large european multi-center study. <i>Journal of Hepatology</i> , 2015, 62, S568.	3.7	5
119	P0690 : IFN-free therapy for chronic HCV: Transcriptomics and NK cell analyses. <i>Journal of Hepatology</i> , 2015, 62, S581.	3.7	0
120	P0695 : Triple therapy for chronic HCV patients induces early activation of intrahepatic NK cells. <i>Journal of Hepatology</i> , 2015, 62, S583.	3.7	0
121	P0761 : Epidemiological trends among patients with chronic HCV infection in a tertiary centre in the Netherlands. <i>Journal of Hepatology</i> , 2015, 62, S614.	3.7	0
122	Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies. <i>Drugs</i> , 2015, 75, 1981-1992.	10.9	42
123	Reduced risk of relapse after longâ€“term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 867-876.	3.7	88
124	Point Shear Wave Elastography by Acoustic Radiation Force Impulse Quantification in Comparison to Transient Elastography for the Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C: A Prospective International Multicenter Study. <i>Ultraschall in Der Medizin</i> , 2015, 36, 239-247.	1.5	25
125	Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during antiviral therapy. <i>Antiviral Research</i> , 2015, 123, 86-92.	4.1	15
126	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , 2015, 64, 322-331.	12.1	30



#	ARTICLE	IF	CITATIONS
127	The impact of <i><sc>PNPLA</sc>3</i> (<i>rs738409</i> C&gt;G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients. <i>Liver International</i> , 2015, 35, 438-447.	3.9	29
128	Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. <i>Hepatology</i> , 2015, 61, 471-480.	7.3	80
129	Polymorphisms of <i><sc>HLA</sc>-<sc>DP</sc></i> are associated with response to peginterferon in Caucasian patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 811-818.	3.7	28
130	Analysis of the transcriptome and immune function of monocytes during IFN±-based therapy in chronic HCV revealed induction of TLR7 responsiveness. <i>Antiviral Research</i> , 2014, 109, 116-124.	4.1	10
131	P1211 HIGH DOSE RIBAVIRIN INFLUENCES EARLY VIRAL KINETICS AND IMPROVES SVR RATES IN CHRONIC HCV PATIENTS WHO ADHERE TO THERAPY (VIRID STUDY). <i>Journal of Hepatology</i> , 2014, 60, S492.	3.7	0
132	Living donor liver transplantation in HCV-infected patients: improvement of the donor risk-recipient benefit ratio is around the corner. <i>Transplant International</i> , 2014, 27, 765-766.	1.6	0
133	The Pan-Genotypic Costs-Effectiveness Of Sofosbuvir in Hepatitis C Virus. <i>Value in Health</i> , 2014, 17, A676.	0.3	1
134	Hepatitis A related acute liver failure by consumption of contaminated food. <i>Journal of Clinical Virology</i> , 2014, 61, 456-458.	3.1	11
135	Costs Per Successfully Treated Patient with Sofosbuvir in GT1 HCV. <i>Value in Health</i> , 2014, 17, A673.	0.3	1
136	Cost Utility of Telaprevir±PR (Peginterferon±Ribavirin) Versus Boceprevir±PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 647-659.	2.1	13
137	Gene Expression Profiling To Predict and Assess the Consequences of Therapy-Induced Virus Eradication in Chronic Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2014, 88, 12254-12264.	3.4	21
138	The number needed to treat to prevent mortality and cirrhosis±related complications among patients with cirrhosis and <sc>HCV</sc> genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 568-577.	2.0	19
139	Controversy on the role of FoxP3+ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections. <i>Journal of Hepatology</i> , 2014, 60, 231-232.	3.7	3
140	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2014, 61, 482-491.	3.7	18
141	Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations. <i>Clinical Pharmacokinetics</i> , 2014, 53, 409-427.	3.5	35
142	Effects of Escitalopram Prophylaxis During Antiviral Treatment for Chronic Hepatitis C in Patients With a History of Intravenous Drug Use and Depression. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 1069-1077.	2.2	4
143	Epidemiology and management of chronic hepatitis E infection in solid organ transplantation: a comprehensive literature review. <i>Reviews in Medical Virology</i> , 2013, 23, 295-304.	8.3	61
144	Natural History of HCV-induced Liver Disease. <i>Current Hepatitis Reports</i> , 2013, 12, 251-260.	0.3	2

#	ARTICLE	IF	CITATIONS
145	504 IMPROVEMENT OF INTERFERON-BASED THERAPY SUBSTANTIALLY REDUCED THE NUMBER NEEDED TO TREAT TO PREVENT HCC AMONG HCV GENOTYPE 1 INFECTED CIRRHOTICS. <i>Journal of Hepatology</i> , 2013, 58, S207.	3.7	3
146	Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: Early effects of active substance use. <i>Antiviral Research</i> , 2013, 97, 347-355.	4.1	6
147	Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients. <i>Antiviral Research</i> , 2013, 98, 469-475.	4.1	3
148	Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA. <i>Journal of Viral Hepatitis</i> , 2013, 20, 158-166.	2.0	73
149	Clinical implications of chronic hepatitis E virus infection in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 78-85.	0.6	63
150	Pharmacokinetics and Antiviral Activity of Phx1766, a Novel HCV Protease Inhibitor, Using An Accelerated Phase I Study Design. <i>Antiviral Therapy</i> , 2012, 17, 365-375.	1.0	11
151	Continuous Interferon- $\beta$ Infusion in Combination with Ribavirin for Chronic Hepatitis C in Treatment-Experienced Patients. <i>Antiviral Therapy</i> , 2012, 17, 509-517.	1.0	3
152	Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7. <i>Antiviral Therapy</i> , 2012, 17, 657-667.	1.0	24
153	Psychiatric Side Effects and Fluctuations in Serotonergic Parameters in the Treatment of Chronic Hepatitis C Infection. <i>Neuropsychobiology</i> , 2012, 65, 126-132.	1.9	8
154	Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2584.	7.4	1,327
155	Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. <i>Liver International</i> , 2012, 32, 622-628.	3.9	68
156	IL28B polymorphism and hepatitis C: A genetic marker of peginterferon- $\beta$ sensitivity devoid from classical interferon- $\beta$ side effects?. <i>Journal of Hepatology</i> , 2012, 56, 741-742.	3.7	0
157	Ezetimibe: A biomarker for efficacy of liver directed UGT1A1 gene therapy for inherited hyperbilirubinemia. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 1223-1229.	3.8	5
158	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. <i>BMC Gastroenterology</i> , 2012, 12, 11.	2.0	30
159	Negative Regulation of Hepatitis C Virus Specific Immunity Is Highly Heterogeneous and Modulated by Pegylated Interferon-Alpha/Ribavirin Therapy. <i>PLoS ONE</i> , 2012, 7, e49389.	2.5	11
160	Telaprevir/boceprevir era: From bench to bed and back. <i>World Journal of Gastroenterology</i> , 2012, 18, 6183.	3.3	22
161	Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 962-972.	1.5	48
162	Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon- $\beta$ /ribavirin treatment for chronic hepatitis C. <i>Antiviral Therapy</i> , 2011, 16, 771-774.	1.0	0

#	ARTICLE	IF	CITATIONS
163	Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon $\alpha$ 2a and ribavirin for chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1306-1317.	3.7	40
164	Serum Markers and Intestinal Mucosal Injury in Chronic Gastrointestinal Ischemia. <i>Digestive Diseases and Sciences</i> , 2011, 56, 506-512.	2.3	28
165	Retention of CD4 <sup>+</sup> CD25 <sup>+</sup> FoxP3 <sup>+</sup> Regulatory T Cells in the Liver after Therapy-Induced Hepatitis C Virus Eradication in Humans. <i>Journal of Virology</i> , 2011, 85, 5323-5330.	3.4	38
166	Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor. <i>Antiviral Therapy</i> , 2010, 15, 765-773.	1.0	4
167	Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. <i>Hepatology</i> , 2010, 52, 1225-1231.	7.3	50
168	Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. <i>Hepatology</i> , 2010, 52, 1590-1599.	7.3	34
169	Crigler-Najjar syndrome in The Netherlands: Identification of four novel <i>UGT1A1</i> alleles, genotype $\rightarrow$ phenotype correlation, and functional analysis of 10 missense mutants. <i>Human Mutation</i> , 2010, 31, 52-59.	2.5	43
170	Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. <i>Journal of Hepatology</i> , 2010, 52, 315-321.	3.7	132
171	Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. <i>Journal of Hepatology</i> , 2010, 53, 455-459.	3.7	46
172	Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon $\alpha$ 2b/ribavirin combination therapy after 4 weeks of treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1.	1.6	2
173	Telaprevir for Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2009, 361, 533-535.	27.0	4
174	941 JTK-652 IS A NOVEL HCV ENTRY INHIBITOR: RESULTS OF A PHASE 1 STUDY EVALUATING SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY IN CHRONIC HEPATITIS C PATIENTS. <i>Journal of Hepatology</i> , 2009, 50, S342.	3.7	1
175	Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. <i>Hepatology</i> , 2008, 47, 1856-1862.	7.3	262
176	Randomized placebo controlled phase I/II trial of $\beta$ -galactosylceramide for the treatment of chronic hepatitis C. <i>Journal of Hepatology</i> , 2007, 47, 356-365.	3.7	62
177	P1889 Pharmacokinetic profiles in chronic hepatitis C patients treated with high-dose pegylated interferon. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, S541-S542.	2.5	0
178	Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan $\frac{1}{2}$ predicts the absence of significant liver fibrosis. <i>Liver International</i> , 2007, 27, 639-645.	3.9	73
179	$\gamma$ -Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon- $\alpha$ 2b in chronic hepatitis C non-responders. <i>Liver International</i> , 2007, 27, 070816165951003-???	3.9	30
180	Significant liver damage in patients with bleeding disorders and chronic hepatitis C: non-invasive assessment of liver fibrosis using transient elastography. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 25-30.	3.8	22

#	ARTICLE	IF	CITATIONS
181	Non-invasive measurement of liver fibrosis: Application of the FibroScan® in hepatology. Scandinavian Journal of Gastroenterology, 2006, 41, 85-88.	1.5	24
182	Current therapy of hepatitis C. Scandinavian Journal of Gastroenterology, 2006, 41, 65-69.	1.5	1
183	Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2005, 21, 539-547.	3.7	3
184	Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: Results of a pilot randomized controlled clinical trial. Journal of Hepatology, 2005, 43, 630-636.	3.7	97
185	Long-term effect of treatment of acute Budd-Chiari syndrome with a transjugular intrahepatic portosystemic shunt. Hepatology, 2002, 35, 1551-1552.	7.3	12
186	Insulin-like growth factor-I in liver cirrhosis. Journal of Hepatology, 1997, 27, 1133-1138.	3.7	24